178 related articles for article (PubMed ID: 38387988)
1. Impact of immunosuppressive therapy on SARS-CoV-2 mRNA vaccine effectiveness in patients with immune-mediated inflammatory diseases: a Danish nationwide cohort study.
Elmahdi R; Ward D; Ernst MT; Poulsen G; Hallas J; Pottegård A; Jess T
BMJ Open; 2024 Feb; 14(2):e077408. PubMed ID: 38387988
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 infection and COVID19 vaccination across eight immune-mediated inflammatory disorders: A prospective, real-life Belgian cohort study - the BELCOMID study.
Geldof J; Truyens M; Sabino J; Ferrante M; Lambert J; Lapeere H; Hillary T; Van Laethem A; de Vlam K; Verschueren P; Padalko E; Lobaton T; Vermeire S
Front Immunol; 2023; 14():1126351. PubMed ID: 36936974
[TBL] [Abstract][Full Text] [Related]
3. Breakthrough infections with the SARS-CoV-2 omicron (B.1.1.529) variant in patients with immune-mediated inflammatory diseases.
Stalman EW; Wieske L; van Dam KPJ; Kummer LY; van Kempen ZLE; Killestein J; Volkers AG; Tas SW; Boekel L; Wolbink GJ; Van der Kooi AJ; Raaphorst J; Löwenberg M; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Parra Sanchez A; van Els CACM; Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart CF; Teng OYK; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; Van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Boogaard A; Cristianawati O; Ten Brinke A; Verstegen NJM; Zwinderman KAH; Rispens T; van Ham SM; Kuijpers TW; Eftimov F;
Ann Rheum Dis; 2022 Dec; 81(12):1757-1766. PubMed ID: 36357161
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of COVID-19 vaccines in patients taking immunosuppressants.
Shen C; Risk M; Schiopu E; Hayek SS; Xie T; Holevinski L; Akin C; Freed G; Zhao L
Ann Rheum Dis; 2022 Jun; 81(6):875-880. PubMed ID: 35197265
[TBL] [Abstract][Full Text] [Related]
5. Primary SARS-CoV-2 infection in patients with immune-mediated inflammatory diseases: long-term humoral immune responses and effects on disease activity.
van Dam KPJ; Volkers AG; Wieske L; Stalman EW; Kummer LYL; van Kempen ZLE; Killestein J; Tas SW; Boekel L; Wolbink GJ; van der Kooi AJ; Raaphorst J; Takkenberg RB; D'Haens GRAM; Spuls PI; Bekkenk MW; Musters AH; Post NF; Bosma AL; Hilhorst ML; Vegting Y; Bemelman FJ; Voskuyl AE; Broens B; Sanchez AP; van Els CACM; de Wit J; Rutgers A; de Leeuw K; Horváth B; Verschuuren JJGM; Ruiter AM; van Ouwerkerk L; van der Woude D; Allaart RCF; Teng YKO; van Paassen P; Busch MH; Jallah PBP; Brusse E; van Doorn PA; Baars AE; Hijnen DJ; Schreurs CRG; van der Pol WL; Goedee HS; Steenhuis M; Keijzer S; Keijser JBD; Cristianawati O; Ten Brinke A; Verstegen NJM; van Ham SM; Rispens T; Kuijpers TW; Löwenberg M; Eftimov F;
BMC Infect Dis; 2023 May; 23(1):332. PubMed ID: 37198536
[TBL] [Abstract][Full Text] [Related]
6. The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls-a prospective cohort study.
Christensen IE; Jyssum I; Tveter AT; Sexton J; Tran TT; Mjaaland S; Kro GB; Kvien TK; Warren DJ; Jahnsen J; Munthe LA; Haavardsholm EA; Vaage JT; Grødeland G; Lund-Johansen F; Jørgensen KK; Syversen SW; Goll GL; Provan SA
BMC Med; 2022 Oct; 20(1):378. PubMed ID: 36199139
[TBL] [Abstract][Full Text] [Related]
7. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study.
Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH
PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766
[TBL] [Abstract][Full Text] [Related]
8. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
9. Vaccine effectiveness against SARS-CoV-2 infection, hospitalization, and death when combining a first dose ChAdOx1 vaccine with a subsequent mRNA vaccine in Denmark: A nationwide population-based cohort study.
Gram MA; Nielsen J; Schelde AB; Nielsen KF; Moustsen-Helms IR; Sørensen AKB; Valentiner-Branth P; Emborg HD
PLoS Med; 2021 Dec; 18(12):e1003874. PubMed ID: 34919548
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy.
Syversen SW; Jyssum I; Tveter AT; Sexton J; Christensen IE; Tran TT; Bjørlykke KH; Mjaaland S; Warren DJ; Kvien TK; Chopra A; Kro GB; Jahnsen J; Munthe LA; Haavardsholm EA; Grødeland G; Vaage JT; Provan SA; Jørgensen KK; Goll GL
RMD Open; 2022 Nov; 8(2):. PubMed ID: 36328399
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of SARS-CoV-2 Vaccination in a Veterans Affairs Cohort of Patients With Inflammatory Bowel Disease With Diverse Exposure to Immunosuppressive Medications.
Khan N; Mahmud N
Gastroenterology; 2021 Sep; 161(3):827-836. PubMed ID: 34048782
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Rituximab Use, Time Between Rituximab and SARS-CoV-2 Vaccination, and COVID-19 Hospitalization or Death in Patients With Multiple Sclerosis.
Smith JB; Gonzales EG; Li BH; Langer-Gould A
JAMA Netw Open; 2022 Dec; 5(12):e2248664. PubMed ID: 36576740
[TBL] [Abstract][Full Text] [Related]
13. Accelerated waning of immunity to SARS-CoV-2 mRNA vaccines in patients with immune-mediated inflammatory diseases.
Dayam RM; Law JC; Goetgebuer RL; Chao GY; Abe KT; Sutton M; Finkelstein N; Stempak JM; Pereira D; Croitoru D; Acheampong L; Rizwan S; Rymaszewski K; Milgrom R; Ganatra D; Batista NV; Girard M; Lau I; Law R; Cheung MW; Rathod B; Kitaygorodsky J; Samson R; Hu Q; Hardy WR; Haroon N; Inman RD; Piguet V; Chandran V; Silverberg MS; Gingras AC; Watts TH
JCI Insight; 2022 Jun; 7(11):. PubMed ID: 35471956
[TBL] [Abstract][Full Text] [Related]
14. Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study.
Nielsen KF; Moustsen-Helms IR; Schelde AB; Gram MA; Emborg HD; Nielsen J; Hansen CH; Andersen MA; Meaidi M; Wohlfahrt J; Valentiner-Branth P
PLoS Med; 2022 Nov; 19(11):e1004037. PubMed ID: 36413551
[TBL] [Abstract][Full Text] [Related]
15. Serological response to vaccines against SARS-CoV-2 in patients with inflammatory bowel disease.
Algaba A; Romero S; Granja A; Garza D; Aller M; Barrero S; Guerra I; Gil M; Pizarro N; Ruiz P; Prieto S; Hernández B; Pou A; Bermejo F
Gastroenterol Hepatol; 2023 Jan; 46(1):48-53. PubMed ID: 35605819
[TBL] [Abstract][Full Text] [Related]
16. Humoral Immunogenicity After Vaccination Against SARS-CoV-2 Infection in Inflammatory Bowel Disease Patients Under Immunosuppressive Therapy: Should We Prioritize an Additional Booster Injection?
Macedo Silva V; Lima Capela T; Freitas M; Cúrdia Gonçalves T; Boal Carvalho P; Dias de Castro F; João Moreira M; Cotter J
Inflamm Bowel Dis; 2023 Feb; 29(2):268-273. PubMed ID: 36099059
[TBL] [Abstract][Full Text] [Related]
17. Incidence and outcome of COVID-19 following vaccine and hybrid immunity in patients on immunosuppressive therapy: identification of protective post-immunisation anti-RBD antibody levels in a prospective cohort study.
Ørbo HS; Bjørlykke KH; Sexton J; Jyssum I; Tveter AT; Christensen IE; Mjaaland S; Kvien TK; Grødeland G; Kro GB; Jahnsen J; Haavardsholm EA; Munthe LA; Provan SA; Vaage JT; Goll GL; Jørgensen KK; Syversen SW
RMD Open; 2024 Apr; 10(2):. PubMed ID: 38599653
[TBL] [Abstract][Full Text] [Related]
18. COVID-19 vaccine effectiveness against omicron (B.1.1.529) variant infection and hospitalisation in patients taking immunosuppressive medications: a retrospective cohort study.
Risk M; Hayek SS; Schiopu E; Yuan L; Shen C; Shi X; Freed G; Zhao L
Lancet Rheumatol; 2022 Nov; 4(11):e775-e784. PubMed ID: 35991760
[TBL] [Abstract][Full Text] [Related]
19. Impact of Holding Immunosuppressive Therapy in Patients with Inflammatory Bowel Disease Around mRNA COVID-19 Vaccine Administration on Humoral Immune Response and Development of COVID-19 Infection.
Motwani KK; Hashash JG; Farraye FA; Kappelman MD; Weaver KN; Zhang X; Long MD; Cross RK
J Crohns Colitis; 2023 Nov; 17(10):1681-1688. PubMed ID: 37232444
[TBL] [Abstract][Full Text] [Related]
20. An Argentinean cohort of patients with rheumatic and immune-mediated diseases vaccinated for SARS-CoV-2: the SAR-CoVAC Registry-protocol and preliminary data.
Isnardi CA; Schneeberger EE; Kreimer JL; Luna PC; Echeverría C; Roberts K; de la Vega MC; Virasoro BM; Landi M; Quintana R; Exeni MED; Kogan N; Petkovic I; Pereira D; De Los Ángeles Correa M; Zelaya MD; Tissera Y; Elkin MSG; Pisoni CN; Alonso C; Cogo AK; Cosatti MA; García L; Retamozo C; de Los Ángeles Severina M; Nieto RE; Rosemffet M; Mussano E; Bertoli A; Savio VG; Cosentino V; Pons-Estel GJ
Clin Rheumatol; 2022 Oct; 41(10):3199-3209. PubMed ID: 35760939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
